Response and outcome of relapsed pediatric BCP-ALL patients with NT5C2 mutations
| Parameter/variable . | Total, n (%) . | NT5C2 wild-type, n (%) . | NT5C2 clonal mut, n (%) . | NT5C2 subclonal mut, n (%) . | P* . | P† . | P‡ . | P§ . |
|---|---|---|---|---|---|---|---|---|
| Total | 455 | 380 | 28 | 47 | ||||
| Cytological response | ||||||||
| Early | 186 (44.3) | 165 (47) | 7 (28) | 14 (31.8) | .001 | .087 | .253 | <.001 |
| Normal | 138 (32.9) | 117 (33.3) | 12 (48) | 9 (20.5) | ||||
| Late | 47 (11.2) | 37 (10.5) | 3 (12) | 7 (15.9) | ||||
| Nonresponse | 49 (11.7) | 32 (9.1) | 3 (12) | 14 (31.8) | ||||
| No data | 35 | 29 | 3 | 3 | ||||
| Response | ||||||||
| Response to treatment | 371 (88.3) | 319 (90.9) | 22 (88) | 30 (68.2) | <.001 | .085 | .717 | <.001 |
| Nonresponse | 49 (11.7) | 32 (9.1) | 3 (12) | 14 (31.8) | ||||
| No data | 35 | 29 | 3 | 3 | ||||
| MRD|| | ||||||||
| Low (<1E-03) | 167 (47.6) | 151 (49.8) | 9 (47.4) | 7 (24.1) | .030 | 0.124 | 1.000 | .011 |
| High (≥1E-03) | 184 (52.4) | 152 (50.2) | 10 (52.6) | 22 (75.9) | ||||
| No data | 104 | 77 | 9 | 18 | ||||
| HSCT after first relapse | ||||||||
| No | 224 (51.6) | 190 (52.6) | 10 (37) | 24 (52.2) | .307 | .234 | .161 | 1.000 |
| Yes | 210 (48.4) | 171 (47.4) | 17 (63) | 22 (47.8) | ||||
| No data | 21 | 19 | 1 | 1 | ||||
| Time to second event (y), median (min-max) | 6.71 (0-17.55) | 7.62 (0-17.55) | 1.20 (0-16.72) | 0.60 (0-17.52) | <.001 | .083 | .009 | <.001 |
| Event after first relapse | ||||||||
| In CCR | 215 (49.1) | 199 (54.5) | 7 (25.9) | 9 (19.6) | .001 | .159 | .025 | <.001 |
| Died in CR2 | 26 (5.9) | 18 (4.9) | 2 (7.4) | 6 (13) | ||||
| Secondary malignancy | 14 (3.2) | 10 (2.7) | 2 (7.4) | 2 (4.3) | ||||
| Second relapse | 121 (27.6) | 96 (26.3) | 13 (48.1) | 12 (26.1) | ||||
| Nonresponse | 49 (11.2) | 32 (8.8) | 3 (11.1) | 14 (30.4) | ||||
| Died during induction | 13 (3) | 10 (2.7) | 0 (0) | 3 (6.5) | ||||
| No data | 17 | 15 | 1 | 1 |
| Parameter/variable . | Total, n (%) . | NT5C2 wild-type, n (%) . | NT5C2 clonal mut, n (%) . | NT5C2 subclonal mut, n (%) . | P* . | P† . | P‡ . | P§ . |
|---|---|---|---|---|---|---|---|---|
| Total | 455 | 380 | 28 | 47 | ||||
| Cytological response | ||||||||
| Early | 186 (44.3) | 165 (47) | 7 (28) | 14 (31.8) | .001 | .087 | .253 | <.001 |
| Normal | 138 (32.9) | 117 (33.3) | 12 (48) | 9 (20.5) | ||||
| Late | 47 (11.2) | 37 (10.5) | 3 (12) | 7 (15.9) | ||||
| Nonresponse | 49 (11.7) | 32 (9.1) | 3 (12) | 14 (31.8) | ||||
| No data | 35 | 29 | 3 | 3 | ||||
| Response | ||||||||
| Response to treatment | 371 (88.3) | 319 (90.9) | 22 (88) | 30 (68.2) | <.001 | .085 | .717 | <.001 |
| Nonresponse | 49 (11.7) | 32 (9.1) | 3 (12) | 14 (31.8) | ||||
| No data | 35 | 29 | 3 | 3 | ||||
| MRD|| | ||||||||
| Low (<1E-03) | 167 (47.6) | 151 (49.8) | 9 (47.4) | 7 (24.1) | .030 | 0.124 | 1.000 | .011 |
| High (≥1E-03) | 184 (52.4) | 152 (50.2) | 10 (52.6) | 22 (75.9) | ||||
| No data | 104 | 77 | 9 | 18 | ||||
| HSCT after first relapse | ||||||||
| No | 224 (51.6) | 190 (52.6) | 10 (37) | 24 (52.2) | .307 | .234 | .161 | 1.000 |
| Yes | 210 (48.4) | 171 (47.4) | 17 (63) | 22 (47.8) | ||||
| No data | 21 | 19 | 1 | 1 | ||||
| Time to second event (y), median (min-max) | 6.71 (0-17.55) | 7.62 (0-17.55) | 1.20 (0-16.72) | 0.60 (0-17.52) | <.001 | .083 | .009 | <.001 |
| Event after first relapse | ||||||||
| In CCR | 215 (49.1) | 199 (54.5) | 7 (25.9) | 9 (19.6) | .001 | .159 | .025 | <.001 |
| Died in CR2 | 26 (5.9) | 18 (4.9) | 2 (7.4) | 6 (13) | ||||
| Secondary malignancy | 14 (3.2) | 10 (2.7) | 2 (7.4) | 2 (4.3) | ||||
| Second relapse | 121 (27.6) | 96 (26.3) | 13 (48.1) | 12 (26.1) | ||||
| Nonresponse | 49 (11.2) | 32 (8.8) | 3 (11.1) | 14 (30.4) | ||||
| Died during induction | 13 (3) | 10 (2.7) | 0 (0) | 3 (6.5) | ||||
| No data | 17 | 15 | 1 | 1 |
Values of P < .05 are depicted in bold.
CCR, continuous complete remission; CR2, second complete remission; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; mut, mutation.
P value calculated among all 3 groups.
P value calculated between clonal and subclonal NT5C2 mutations.
P value calculated between clonal NT5C2 mutations and wild-type.
P value calculated between subclonal NT5C2 mutations and wild-type.
MRD measured at the end of induction therapy (5 wk): low level, <1E−03 leukemic cells; high level, ≥1E−03 leukemic cells in BM aspirate.